Golotimod

DB05475InvestigationalSmall molecule

SCV-07 (g -D-glutamyl-L-tryptophan) is a novel synthetic dipeptide that acts broadly on the Toll-like receptor pathway. It has been shown to stimulate T-lymphocyte differentiation, macrocytic phagocytosis, and specific immune responses,... Due to this preferential activation of Th1 cytokine production, SCV-07 may show utility in treatment of tuberculosis.

Mechanism: SCV-07 (g -D-glutamyl-L-tryptophan) has broad effects on the Toll-like receptor (TLR) pathway.
Curator reviewed
Primary indication: Investigated for use/treatment in hepatitis (viral, C), infectious and parasitic disease (unspecified), and tuberculosis.Curator reviewed
Formula / weight: C₁₆H₁₉N₃O₅ · 333.3392 g/mol (avg)
Code names: SCV-07

Resolves to

Compound

UNII637C487Y09CAS229305-39-9ChEMBLCHEMBL2103812PubChem6992140

Clinical / RWD

RxNorm2367440

Structure

InChIKeyCATMPQFFVNKDEY-YPMHNXCESA-NSMILESN[C@H](CCC(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(O)=O)C(O)=O

Targets

P40763STAT3O60603TLR2O00206TLR4Q9NYK1TLR7Q9NR96TLR9

What you can answer from here — as of January 29, 2025

5Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Golotimod, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account